Evidence map›Paper›PMID 39260053›Full record

ArticleVaccine2024

Maternal influenza vaccination and associated risk of fetal loss: A claims-based prospective cohort study.

Annette K Regan, Sheena G Sullivan, Onyebuchi A Arah

Abstract read
In one paragraph

Article in Vaccine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Annette K ReganSchool of Nursing and Health Professions, University of San Francisco, San Francisco, CA, United States; Department of Epidemiology, Fielding School of Public Health, UCLA, Los Angeles, CA, United States. Electronic address: akregan@usfca.edu.
Sheena G SullivanDepartment of Epidemiology, Fielding School of Public Health, UCLA, Los Angeles, CA, United States; WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, and Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Onyebuchi A ArahDepartment of Epidemiology, Fielding School of Public Health, UCLA, Los Angeles, CA, United States; Department of Statistics and Data Science, UCLA, Los Angeles, CA, United States; Practical Causal Inference Lab, UCLA, Los Angeles, CA, United States; Department of Public Health, Research Unit for Epidemiology, Aarhus University, Aarhus, Denmark.

Funding

Scientific and Technical CoreP2CHD041022 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Martha Jane Bailey · 2016 to 2026
$6.9M
NICHD NIH HHS P2C HD041022
6 · The paper itself

Abstract

backgroundAlthough numerous studies support the safety of influenza vaccination during pregnancy, fewer studies have evaluated the risk of miscarriage or considered the effect of prior immunization.

methodsUsing national de-identified administrative claims data from the Optum Labs Data Warehouse, we conducted a claims-based cohort study of 117,626 pregnancies between January 2009 and December 2018. We identified pandemic A(H1N1)pdm09 and seasonal influenza vaccinations using CPT codes. Fetal loss was defined as miscarriage, medical termination, or stillbirth as identified by ICD-10-CM diagnostic codes. Cox proportional hazard models treating influenza vaccination as a time-varying exposure, weighted for loss-to-follow-up and stratified by baseline probability of vaccination, were used to model the risk of fetal loss by exposure to influenza vaccine.

resultsAbout 31.4 % of the cohort had a record of influenza vaccination; 10.0 % were vaccinated before pregnancy only, 17.8 % during pregnancy only, and 3.6 % before and during pregnancy. The risk of miscarriage was 39 % lower among those vaccinated during pregnancy compared to unvaccinated (adjusted hazard ratio, aHR 0.61; 95 % CI 0.50, 0.74) and was similar for medical termination or stillbirth (HR 0.69; 95 % CI 0.45, 1.03 and aHR 0.99; 95 % CI 0.76, 1.30, respectively). Similar results were observed for women who received the vaccine before and during pregnancy. We observed little to no association between vaccination before pregnancy and risk of miscarriage (HR 0.98; 95 % CI 0.76, 1.26), medical termination (HR 1.02; 95 % CI 0.46, 2.24), or stillbirth (HR 1.14, 95 % CI 0.77, 1.69). DISCUSSION: Influenza vaccination was not associated with an increased risk of fetal loss. These results support the safety of influenza vaccine administration even when administered before or early during pregnancy.

Indexed as

Abortion, SpontaneousInfluenza, HumanInfluenza VaccinesVaccinationAdultFemaleHumansInfluenza A Virus, H1N1 SubtypePregnancyPregnancy Complications, InfectiousProportional Hazards ModelsProspective StudiesYoung AdultInfluenza VaccinesInactivated influenza vaccineMaternal vaccinationMiscarriagePregnancyVaccine safety

Identifiers

PMID39260053
PMCPMC11911014

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.